These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

509 related items for PubMed ID: 17409317

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
    de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.
    Circulation; 2004 Aug 24; 110(8):921-7. PubMed ID: 15302780
    [Abstract] [Full Text] [Related]

  • 6. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
    Keane WF, Lyle PA, Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan study.
    Am J Kidney Dis; 2003 Mar 24; 41(3 Suppl 1):S22-5. PubMed ID: 12612946
    [Abstract] [Full Text] [Related]

  • 7. Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.
    Tershakovec AM, Keane WF, Zhang Z, Lyle PA, Appel GB, McGill JB, Parving HH, Cooper ME, Shahinfar S, Brenner BM.
    Diabetes Care; 2008 Mar 24; 31(3):445-7. PubMed ID: 18070995
    [Abstract] [Full Text] [Related]

  • 8. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
    Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahlöf B, Ibsen H, Lindholm LH, Lyle PA, Snapinn SM, Zhang Z, Edelman JM, Shahinfar S.
    Am J Cardiol; 2005 Dec 01; 96(11):1530-6. PubMed ID: 16310435
    [Abstract] [Full Text] [Related]

  • 9. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
    Remuzzi G, Ruggenenti P, Perna A, Dimitrov BD, de Zeeuw D, Hille DA, Shahinfar S, Carides GW, Brenner BM, RENAAL Study Group.
    J Am Soc Nephrol; 2004 Dec 01; 15(12):3117-25. PubMed ID: 15579515
    [Abstract] [Full Text] [Related]

  • 10. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
    Arredondo A, Burke TA, Carides GW, Lemus E, Querol J.
    Rev Invest Clin; 2005 Dec 01; 57(3):399-405. PubMed ID: 16187699
    [Abstract] [Full Text] [Related]

  • 11. Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: A randomized controlled trial.
    Agha A, Amer W, Anwar E, Bashir K.
    Saudi J Kidney Dis Transpl; 2009 May 01; 20(3):429-35. PubMed ID: 19414946
    [Abstract] [Full Text] [Related]

  • 12. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
    Burgess ED, Carides GW, Gerth WC, Marentette MA, Chabot I, Canadian Hypertension Society.
    Can J Cardiol; 2004 May 01; 20(6):613-8. PubMed ID: 15152291
    [Abstract] [Full Text] [Related]

  • 13. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B.
    Curr Med Res Opin; 2004 Mar 01; 20(3):333-40. PubMed ID: 15025842
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy.
    Schjoedt KJ, Lajer M, Andersen S, Tarnow L, Rossing P, Parving HH.
    Scand J Clin Lab Invest; 2006 Mar 01; 66(3):173-80. PubMed ID: 16714246
    [Abstract] [Full Text] [Related]

  • 17. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
    Parving HH, Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S.
    Ugeskr Laeger; 2001 Oct 01; 163(40):5514-9. PubMed ID: 11601117
    [Abstract] [Full Text] [Related]

  • 18. Losartan in diabetic nephropathy.
    Perico N, Ruggenenti P, Remuzzi G.
    Expert Rev Cardiovasc Ther; 2004 Jul 01; 2(4):473-83. PubMed ID: 15225108
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.
    Winkelmayer WC, Zhang Z, Shahinfar S, Cooper ME, Avorn J, Brenner BM.
    Diabetes Care; 2006 Oct 01; 29(10):2210-7. PubMed ID: 17003295
    [Abstract] [Full Text] [Related]

  • 20. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
    Agha A, Bashir K, Anwar E.
    Nepal Med Coll J; 2007 Jun 01; 9(2):79-83. PubMed ID: 17899953
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.